Table 1.
Characteristics of patient sample (n = 47). Mean (SD), range unless otherwise indicated.
| Demographics | Complete sample | Patients (n = 17) | Survivors (n = 30) |
|---|---|---|---|
| Sex female n (%) | 25 (53) | 9 (53) | 16 (53) |
| Age | 57.13 (10.61), 26 – 82 | 55.06 (11.42), 32 – 6757.86 (10.83), 32 – 71 |
58.30 (10.14), 26 – 82 |
| BMI | 29.56 (7.08), 19.14 – 47.49 | 27.30 (5.84), 19.98 – 39.46 | 30.84 (7.48), 13.14 – 49.49 |
| Race/ethnicity n (%) | |||
| Caucasian | 41 (87) | 16 (94) | 25 (83) |
| Hispanic | 4 (9) | 1 (6) | 3 (10) |
| African American | 2 (4) | 0 (0) | 2 (7) |
| Clinical characteristics | |||
| Cancer diagnosis n (%) | |||
| Head & neck cancer | 14 (30) | 2 (12) | 12 (41) |
| Breast cancer | 12 (25) | 5 (29) | 7 (23) |
| Hematologic cancer | 13 (28) | 7 (41) | 6 (20) |
| Other | 8 (17) | 3 (18) | 5 (17) |
| Cancer treatment n (%) | - | Currently receiving: | Last received: |
| Chemo(radiation) | 10 (59) | 11 (37) | |
| Radiation | 1 (6) | 17 (57) | |
| Endocrine | 2 (12) | ||
| Other | 1 (6) | ||
| Use of psychotropic drugs a n (%) | |||
| anxiolytic/hypnotics | 15 (32) | 8 (47) | 7 (23) |
| antidepressants | 17 (36) | 7 (42) | 10 (33) |
| psychostimulants | 16 (34) | 8 (27) | 8 (47) |
| Self-report measures | |||
| General fatigue | 10.87 (5.80), 0 – 22 | 13.41 (4.80), 6 – 22 | 9.43 (5.89), 0 – 22 |
| Motivational fatigue | 13.81 (6.09), 4 – 26 | 15.88(6.31), 5 – 26 | 12.63 (5.73), 4 – 25 |
| Momentary fatigue (VAS) | |||
| Pre EEfRT | 3.59 (2.25), 0.35 – 8.80 | 3.51 (2.40), 0.40 – 8.00 | 3.63 (2.20), 0.35 – 8.80 |
| Post EEfRT | 4.52 (2.57), 0.30 – 9.25 | 4.53 (2.78), 0.36 – 9.00 | 4.42 (2.49), 0.30 – 9.25 |
| Negative affect | 16.15 (5.79), 10 – 29 | 17.41 (7.09), 10 – 29 | 15.43 (4.89), 10 – 28 |
| Positive affect | 31.38 (7.75), 15 – 45 | 29.42 (8.83), 15 – 43 | 32.50 (6.98), 18 – 45 |
| Anhedonia | 1.68 (2.31), 0 – 8 | 2.24 (2.82), 0 – 8 | 1.37 (1.96), 0 – 7 |
| Depressive symptoms b n (%) | 27 (57) | 10 (59) | 17 (57) |
| Inflammation biomarkersc Median, IQR | |||
| CRP (mg/l) | 2.50, 0.75 – 6.29 | 4.18, 0.73 – 5.74 | 2.47, 0.72 – 6.79 |
| TNF-α (pg/ml) | 0.93, 0.52 – 1.45 | 1.00, 0.78 – 2.00 | 0.86, 0.48 – 1.26 |
| sTNFRII (pg/ml) | 2983.33, 2331.04 – 3821.96 | 3584.17, 2155.06 – 4023.52 | 2912.09, 2368.22 – 3727.56 |
| IL-6 (pg/ml) | 1.49, 0.71 – 4.24 | 1.40, 0.71 – 1.87 | 2.02, 0.70 – 4.74 |
| sIL-6r (ng/mL) | 36.13, 27.98 – 44.01 | 36.46, 27.99 – 41.65 | 34.57, 27.77 – 45.96 |
| IL-1ra (pg/ml) | 274.70, 173.06 – 451.38 | 269.57, 211.55 – 415.38 | 279.83. 150.04 – 588.63 |
a
Several participants used medication from more than one category;
b
Questionnaire score ≥ 2; vs. no depressive symptoms (score 0 or 1);
c
n = 44. IQR: Interquartile range.